Chemical formula: C₃₀H₃₈N₂O₂ Molecular mass: 458.293 g/mol PubChem compound: 23642301
Elacestrant is indicated for:
Population group: only adults (18 years old or older)
Elacestrant monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1 mutation who have disease progression following at least one line of endocrine therapy including a CDK 4/6 inhibitor.
For this indication, competent medicine agencies globally authorize below treatments (click for details):
Elacestrant is contraindicated in the following cases:
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
